Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.66 |
| ▸ | ADRB3 | P13945 | 17/20 | 0.51 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.45 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8632112 | 0.83 | ADRA2A (0.69) | ADRA2AADRA2BADRA2CADRA1AADRB3 | |
| SCHEMBL13293368 | 0.81 | ADRA2A (0.75) | ADRA2AADRA2BADRA2CADRA1AADRB3 | |
| SCHEMBL8787480 | 0.80 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL9687730 | 0.79 | ADRA2A (0.73) | ADRA2AADRA2BADRA2CADRA1AADRB3 | |
| SCHEMBL30841998 | 0.78 | ADRA2A (0.62) | ADRA2AADRA2BADRA2CADRA1AADRB3 | |
| Hydrochloric Acid SCHEMBL11670739 | 0.78 | ADRA2B (0.70) | ADRA2AADRA2BADRA2CADRA1AADRB3 | |
| SCHEMBL7242198 | 0.77 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CADRA1AADRB3 | |
| SCHEMBL7723614 | 0.75 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CADRA1AADRB3 | |
| SCHEMBL8787958 | 0.75 | POLB (0.51) | ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL7674723 | 0.75 | KDM6B (0.59) | ADRA2AADRA2BADRA2CADRA1AADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0659737-B1 | Catecholamine surrogates useful as beta 3 agonists | BRISTOL MYERS SQUIBB CO (US) | 2003-03-26 | — | — | EP | disclosed |
| US-5776983-A | ANTIDIABETIC AGENTS, OBESITY, GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0659737-A2 | Catecholamine surrogates useful as B3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |